Moreover, ACS reduced cell viability of primary AML samples carrying FLT3 (Fig. 5E, G) or RAS (Fig. 5F, H) mutations and accentuated the leukemia inhibitory and apoptotic effects of quizartinib, ibrutinib, and doxorubicin. This evidence concerns the gene FLT3 and leukemia.